AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33602374 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and nutrition supplementation
Number of subjects: 114
Study 33602374 — intervention group
Group type: EXPERIMENTAL
Intervention: Condiments (42.4%), cereals and their products (16.8%), soups (13.5%)
Number of subjects: 114
Study 33602374 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of seafood and nuts
Number of subjects: 114
Study 35252940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of testosterone (quartile 4)
Number of subjects: 5535
Study 35252940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of DHEA (quartile 4)
Number of subjects: 5535
Study 35252940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of oestrone (quartile 2)
Number of subjects: 5535
Study 35252940 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG
Number of subjects: 5535
Study 35252940 — intervention group
Group type: EXPERIMENTAL
Intervention: Any hormone or SHBG
Number of subjects: 5535
Study 32000723 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Checklist‐Civilian Version used for screening PTSD
Number of subjects: 149
Study 32000723 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic risk factors (gender, income, age at loss, medical conditions, duration of being Shidu)
Number of subjects: 149
Study 32000723 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 149
Study 33739127 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month aspirin therapy with continued ticagrelor
Number of subjects: 2660
Study 33739127 — intervention group
Group type: COMPARATOR
Intervention: 12-month aspirin and ticagrelor
Number of subjects: 2660
Study 32619458 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 85
Study 32619458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stressor)
Number of subjects: 85
Study 32619458 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PEP and HF
Number of subjects: 85
Study 36436387 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and cognitive training
Number of subjects: 0
Study 36436387 — intervention group
Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 0
Study 33333430 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence programme (TAP)
Number of subjects: 151
Study 33333430 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study 33181658 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plate
Number of subjects: 0
Study 33181658 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nail
Number of subjects: 0
Study 35343369 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 66
Study 35343369 — intervention group
Group type: COMPARATOR
Intervention: Sham Kinesio taping
Number of subjects: 66
Study 33413273 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics including younger age, higher body mass index (BMI), greater WOMAC pain scores, dysfunction scores, stiffness scores, lower education level, more than one comorbidity, and two or more painful body sites
Number of subjects: 397
Study 33413273 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher WOMAC pain and dysfunction scores at baseline
Number of subjects: 397
Study 33413273 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 397
Study 32768569 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 125
Study 32768569 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 125
Study 32768569 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic subgroup (both interventions)
Number of subjects: 125
Study 35441464 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesic prescription at hospital discharge
Number of subjects: 104
Study 35441464 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesic use 4 weeks after ED presentation
Number of subjects: 104
Study 35441464 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of continued opioid use
Number of subjects: 104
Study 34585874 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+AV
Number of subjects: 150
Study 34585874 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+PDT
Number of subjects: 150
Study 34585874 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 150
Study 32781905 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced pluripotent stem cell-derived megakaryocyte clones with gene knockdown of GP-5, GRN, and MPO
Number of subjects: 71
Study 32781905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 71
Study 32781905 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-PLT/MPV association analysis
Number of subjects: 71
Study 32781905 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-sequencing analysis
Number of subjects: 71
Study 32781905 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Number of subjects: 71
Study 36589612 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic plus stretching (Group 1)
Number of subjects: 41
Study 36589612 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance plus stretching (Group 2)
Number of subjects: 41
Study 36589612 — intervention group
Group type: COMPARATOR
Intervention: Home-based stretching (Group 3)
Number of subjects: 41
Study 32747494 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve replacement (surgical or percutaneous)
Number of subjects: 0
Study 32747494 — intervention group
Group type: COMPARATOR
Intervention: Natural history observation
Number of subjects: 0
Study 34020962 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg two times per day)
Number of subjects: 23
Study 34020962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules two times per day)
Number of subjects: 23
Study 34020962 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 23
Study 34020962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 34020962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Methylphenidate and Placebo)
Number of subjects: 23
Study 32990610 — intervention group
Group type: EXPERIMENTAL
Intervention: Konjac powder beverage 30 minutes before each meal
Number of subjects: 76
Study 32990610 — intervention group
Group type: COMPARATOR
Intervention: Resistant maltodextrin beverage
Number of subjects: 76
Study 34882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A - written aphasia-friendly information provision
Number of subjects: 35
Study 34882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B - collaborative goal-setting
Number of subjects: 35
Study 34882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted behaviour change domains
Number of subjects: 35
Study 33430735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod supplementation
Number of subjects: 40
Study 33430735 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Pidotimod supplementation)
Number of subjects: 40
Study 33138838 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoMaster
Number of subjects: 67
Study 33138838 — intervention group
Group type: COMPARATOR
Intervention: Miniaci
Number of subjects: 67
Study 35202193 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofosfamide (Evo) + Doxorubicin (Dox)
Number of subjects: 296
Study 35202193 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (Dox)
Number of subjects: 296
Study 33744193 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 85
Study 33744193 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 85
Study 35217226 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50
Study 35217226 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study 35217226 — intervention group
Group type: EXPERIMENTAL
Intervention: No strong preference for anesthesia techniques
Number of subjects: 50
Study 35217226 — intervention group
Group type: COMPARATOR
Intervention: Strong preference for anesthesia techniques
Number of subjects: 50
Study 33982941 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIVE (30-minute strength training video plus health coach)
Number of subjects: 83
Study 33982941 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 83
Study 35661954 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapy (LRT) for the primary site of breast cancer
Number of subjects: 4
Study 35661954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no locoregional therapy)
Number of subjects: 4
Study 33406234 — intervention group
Group type: EXPERIMENTAL
Intervention: SHORT inter‐set rest interval (one‐minute)
Number of subjects: 10
Study 33406234 — intervention group
Group type: COMPARATOR
Intervention: LONG inter‐set rest interval (three‐minute)
Number of subjects: 10
Study 32738479 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5-μg vaccine
Number of subjects: 360
Study 32738479 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-μg vaccine
Number of subjects: 360
Study 32738479 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-μg vaccine
Number of subjects: 360
Study 32738479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 35457633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 24)
Number of subjects: 41
Study 35457633 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 41
Study 32397596 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session (RH group)
Number of subjects: 28
Study 32397596 — intervention group
Group type: EXPERIMENTAL
Intervention: Match (RH group)
Number of subjects: 28
Study 32397596 — intervention group
Group type: COMPARATOR
Intervention: Training session (comparison between NH and RH groups)
Number of subjects: 28
Study 32397596 — intervention group
Group type: COMPARATOR
Intervention: Match (comparison between NH and RH groups)
Number of subjects: 28
Study 36412015 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeahhh Baby!® ointment
Number of subjects: 20
Study 36412015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32423561 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraflex stent (sirolimus-eluting, ultrathin strut)
Number of subjects: 0
Study 32423561 — intervention group
Group type: COMPARATOR
Intervention: Xience stent (everolimus-eluting, thicker strut)
Number of subjects: 0
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity at month 01 (M01)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Central subfield thickness (CST) at month 01 (M01)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal fluid at month 01 (M01)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraretinal fluid at month 01 (M01)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorganization of retinal inner layers (DRIL) at month 01 (M01)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ) at month 01 (M01)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity at month 06 (M06)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity at month 12 (M12)
Number of subjects: 362
Study 33373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity at month 24 (M24)
Number of subjects: 362
Study 33573421 — intervention group
Group type: EXPERIMENTAL
Intervention: Local pain (Capsaicin gel applied)
Number of subjects: 90
Study 33573421 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote pain (Capsaicin gel applied)
Number of subjects: 90
Study 33573421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 33573421 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including local and remote pain)
Number of subjects: 90
Study 33684624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 oral dose of 50 mg of naltrexone
Number of subjects: 20
Study 33684624 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study 32907896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Monitoring (AM): 3-monthly serum prostate-specific antigen (PSA) assessment in year 1, 6-12 monthly thereafter; review triggered by increase in PSA ≥50% during previous 12 months or patient/clinician concern.
Number of subjects: 20
Study 32907896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Monitoring (AM)
Number of subjects: 20
Study 35271958 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric circle method, 3 mL
Number of subjects: 32
Study 35271958 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric circle method, 10 mL
Number of subjects: 32
Study 35271958 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-and-forth friction method, 3 mL
Number of subjects: 32
Study 35271958 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-and-forth friction method, 10 mL
Number of subjects: 32
Study 35271958 — intervention group
Group type: COMPARATOR
Intervention: Back-and-forth friction methods (C and D) vs. concentric circles (A and B)
Number of subjects: 32
Study 34422279 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraception Choices online trial
Number of subjects: 18
Study 33330119 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 N-protein test strip
Number of subjects: 0
Study 35926996 — intervention group
Group type: EXPERIMENTAL
Intervention: F@ce 2.0 intervention
Number of subjects: 160
Study 33454970 — intervention group
Group type: EXPERIMENTAL
Intervention: SCSH before endometrial aspiration
Number of subjects: 232
Study 33454970 — intervention group
Group type: COMPARATOR
Intervention: Endometrial aspiration before SCSH
Number of subjects: 232
Study 32616489 — intervention group
Group type: EXPERIMENTAL
Intervention: Impryl (nutritional supplement), one tablet each day for a total duration of 6 months
Number of subjects: 1200
Study 32616489 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one tablet each day for a total duration of 6 months
Number of subjects: 1200
Study 32616489 — intervention group
Group type: EXPERIMENTAL
Intervention: Impryl (nutritional supplement)
Number of subjects: 1200
Study 35802374 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 321
Study 35802374 — intervention group
Group type: COMPARATOR
Intervention: Exercise-based physical therapy
Number of subjects: 321
Study 35802374 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 321
Study 33967176 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral VIM-FUS thalamotomy
Number of subjects: 11
Study 32336038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenabasum (5 mg once daily, 20 mg once daily, or 20 mg twice daily for 4 weeks, followed by 20 mg twice daily for 8 weeks)
Number of subjects: 42
Study 32336038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 34699396 — intervention group
Group type: COMPARATOR
Intervention: AC-CROS
Number of subjects: 10
Study 34699396 — intervention group
Group type: EXPERIMENTAL
Intervention: aBC-CROS
Number of subjects: 10
Study 34699396 — intervention group
Group type: COMPARATOR
Intervention: Unaided
Number of subjects: 10
Study 33866860 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE intervention (system provider level training intervention)
Number of subjects: 0
Study 33866860 — intervention group
Group type: COMPARATOR
Intervention: Control CMH teams
Number of subjects: 0
Study 32729217 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 3304
Study 32729217 — intervention group
Group type: COMPARATOR
Intervention: First-generation standard-of-care basal insulin analogues (SOC‐BI; insulin glargine 100 U/mL or insulin detemir)
Number of subjects: 3304
Study 36118830 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized health education
Number of subjects: 220
Study 36118830 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 220
Study 32433827 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) added to methotrexate (MTX)
Number of subjects: 258
Study 32433827 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) plus hydroxychloroquine (HCQ) added to methotrexate (MTX)
Number of subjects: 258
Study 32433827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IFX and SSZ plus HCQ)
Number of subjects: 258
Study 33443912 — intervention group
Group type: EXPERIMENTAL
Intervention: SKINCARE bundle intervention
Number of subjects: 0
Study 35943761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of primary canine only
Number of subjects: 28
Study 35943761 — intervention group
Group type: COMPARATOR
Intervention: Extraction of primary canine and primary first molar
Number of subjects: 28
Study 35943761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of both the canine and the first molar
Number of subjects: 28
Study 34210295 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile dysfunction prevalence assessment
Number of subjects: 352
Study 34210295 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with erectile dysfunction
Number of subjects: 352
Study 34528084 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 574
Study 34528084 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 150 mg
Number of subjects: 574
Study 34528084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 33400389 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 100
Study 33400389 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive women)
Number of subjects: 100
Study 34871051 — intervention group
Group type: EXPERIMENTAL
Intervention: TC‐325
Number of subjects: 224
Study 34871051 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 224
Study 32033546 — intervention group
Group type: EXPERIMENTAL
Intervention: RANI project components (norms-based intervention)
Number of subjects: 4000
Study 32033546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4000
Study 35917824 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently introduced bovine pericardial bioprosthesis (study group)
Number of subjects: 140
Study 35917824 — intervention group
Group type: COMPARATOR
Intervention: World-widely used bovine pericardial bioprosthesis (control group)
Number of subjects: 140
Study 35917824 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 mm prostheses in study group
Number of subjects: 140
Study 35917824 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effective orifice area in study group
Number of subjects: 140
Study 35917824 — intervention group
Group type: COMPARATOR
Intervention: Overall effective orifice area in control group
Number of subjects: 140
Study 35917824 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes in study group
Number of subjects: 140
Study 35917824 — intervention group
Group type: COMPARATOR
Intervention: Clinical outcomes in control group
Number of subjects: 140
Study 32033613 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-it intervention (additional visits from municipal health visitors, digital health coaching, structured communication system)
Number of subjects: 460
Study 32033613 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 460
Study 35096104 — intervention group
Group type: EXPERIMENTAL
Intervention: NXT15906F6 (250 mg/day)
Number of subjects: 90
Study 35096104 — intervention group
Group type: EXPERIMENTAL
Intervention: NXT19185 (300 mg/day)
Number of subjects: 90
Study 35096104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34221932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen intra-articular injection
Number of subjects: 40
Study 34221932 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 36440524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibraject-assisted injection (VAI)
Number of subjects: 75
Study 36440524 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 75
Study 33349499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti rotating‐platform TKA
Number of subjects: 108
Study 33349499 — intervention group
Group type: COMPARATOR
Intervention: CoCr rotating‐platform TKA
Number of subjects: 108
Study 32103514 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg intravenous dexamethasone
Number of subjects: 126
Study 32103514 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 126
Study 35123105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 140
Study 35123105 — intervention group
Group type: COMPARATOR
Intervention: 0.068% ropivacaine
Number of subjects: 140
Study 33707983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix (simultaneous usage of vest and beverage)
Number of subjects: 7
Study 33707983 — intervention group
Group type: COMPARATOR
Intervention: CON (control trial without pre‐cooling)
Number of subjects: 7
Study 33707983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vest (cooled to 4 ℃)
Number of subjects: 7
Study 33707983 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage (cooled to 4 ℃)
Number of subjects: 7
Study 32950400 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated bilingual computerized alcohol screening and brief intervention (AB-CASI)
Number of subjects: 820
Study 32950400 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 820
Study 34255051 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) tool
Number of subjects: 830
Study 34255051 — intervention group
Group type: COMPARATOR
Intervention: Standard AF care without SDM tool
Number of subjects: 830